This is a routine 10b5-1 plan filing by an officer; no material impact expected. Monitor for any deviation from the plan or acceleration of sales, but the filing itself does not warrant action.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $81.70entry
- T+1 · 6mo ago −0.29%α −0.85% · $81.46
- T+5 · 6mo ago −10.39%α −10.86% · $73.21
- T+20 · 5mo ago +42.55%α +44.45% · $116.46
- T+60 · 3mo ago +48.71%α +46.84% · $121.50
Price Chart
How similar events traded
Executive Summary
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 on May 26, 2026, indicating intent to sell 13,130 shares of common stock valued at approximately $1.04 million. The shares were acquired through vesting of restricted stock units, and Chadwick has been executing sales under a 10b5-1 plan, with prior sales totaling over $14 million since March 2026. The filing is a routine advance notice under a pre-arranged trading plan and does not signal a change in business fundamentals.
Key Facts
- Officer Jeremy Chadwick filed Form 144 to sell 13,130 shares of common stock.
- Estimated aggregate market value of the proposed sale is $1,035,825.70 based on a filing date of May 26, 2026.
- Chadwick has been selling shares under a 10b5-1 plan, with prior sales totaling approximately $14.2 million from March to April 2026.
- Shares to be sold were acquired upon vesting of restricted stock units between March 2025 and May 2026.
- The filing is an advance notice of intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 13,130 shares valued at ~$1.04 million, representing a small fraction of the $6.5B market cap.
Risk Factors
- Insider selling under a 10b5-1 plan is pre-arranged and not indicative of negative outlook.
- No material risk to company fundamentals from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005075 |
| Document: 0001950047-26-005075-index.html | 0001950047-26-005075 |
| Document: 0001950047-26-005075.txt | 0001950047-26-005075 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers